Last reviewed: June 4, 2026
Last updated: June 4, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1 receptor agonists like semaglutide have transformed weight loss treatment, but pregnancy planning requires different medical considerations. Current research on GLP-1 use during pregnancy remains limited, and most medical organizations recommend discontinuing these medications before conception or early in pregnancy.
What Does Current Research Say About GLP-1 and Pregnancy?
Animal studies have shown potential developmental concerns with GLP-1 receptor agonists, though human pregnancy data remains sparse. The FDA classifies semaglutide and tirzepatide as Category C medications, meaning animal reproduction studies have shown adverse effects, but no adequate human studies exist. This classification means the drugs should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Reproductive toxicology studies in animal models have documented effects on fetal development at doses comparable to human therapeutic levels. Most major medical organizations, including the American College of Obstetricians and Gynecologists, currently recommend stopping GLP-1 medications once pregnancy is confirmed. The lack of robust human trial data makes it difficult to establish absolute safety profiles, which is why a conservative approach has become standard practice.
When Should You Stop Taking GLP-1 Medications Before Getting Pregnant?
Medical professionals typically advise discontinuing GLP-1 receptor agonists before attempting conception, though exact timing depends on individual circumstances and the specific medication. For semaglutide injections, the medication clears from the body within several weeks after the final dose, allowing for a natural washout period. Planning ahead with your healthcare provider ensures you have time to adjust treatment strategies and establish alternative weight management approaches.
Women of childbearing age who are taking GLP-1 medications should discuss pregnancy planning openly with their healthcare team. If pregnancy occurs while using these medications, immediate medical consultation is essential to assess individual risk factors and determine the safest course of action. Do not stop medications abruptly without professional guidance, as this can create metabolic complications.
How Does Gestational Diabetes Risk Change With GLP-1 Use?
Women with obesity face elevated gestational diabetes risk, and GLP-1 medications help manage this risk through improved blood sugar control before pregnancy. However, once pregnant, the hormonal changes of gestation create a new metabolic environment that requires different management strategies. Discontinuing GLP-1 therapy means patients may need alternative glucose management approaches, including dietary modification, increased physical activity, and potentially insulin therapy if gestational diabetes develops.
The pre-pregnancy weight loss achieved through GLP-1 treatment may provide lasting metabolic benefits during pregnancy, even after stopping the medication. Studies show that weight reduction before conception improves pregnancy outcomes and reduces gestational diabetes incidence. Working with an obstetric team experienced in managing previously obese patients helps optimize care throughout gestation and postpartum recovery.
Can You Restart GLP-1 Treatment After Pregnancy and Breastfeeding?
Restarting GLP-1 medications after pregnancy depends on breastfeeding status and individual health factors. GLP-1 medications do transfer into breast milk in small amounts, so most providers recommend waiting until breastfeeding has ended before resuming semaglutide or tirzepatide injections. The postpartum period offers an opportunity to reassess weight management goals and create a comprehensive plan that aligns with family planning intentions.
PlexusDx serves patients across all 50 states with flexible dosing protocols that can be adjusted as life circumstances change. When you're ready to restart treatment after pregnancy and breastfeeding, working with PlexusDx providers allows you to resume personalized therapy without membership fees or insurance requirements. The Precision Peptide Genetic Test (available for $99 after your first month of treatment) helps identify how your body responds to GLP-1 medications, informing your long-term weight management strategy.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is it safe to take semaglutide if I'm trying to get pregnant?
Most medical professionals recommend stopping semaglutide before attempting conception because human pregnancy safety data is limited. Talk with your doctor about timing the discontinuation and alternative weight management strategies during your conception attempts.
What does the research show about GLP-1 medications and birth defects?
Animal studies have raised concerns about potential developmental effects, which is why FDA classification is Category C. However, human studies are extremely limited, and no confirmed birth defects have been established in humans.
Can I use GLP-1 medications while breastfeeding?
GLP-1 medications pass into breast milk, so most lactation specialists and physicians recommend avoiding them during breastfeeding. If weight management is urgent, discuss alternative approaches with your healthcare team. Once breastfeeding ends, you can restart semaglutide injections (starting at $149/mo) or other GLP-1 therapies through PlexusDx.
Does losing weight with GLP-1 before pregnancy improve health outcomes?
Yes—significant evidence shows that pre-pregnancy weight loss reduces gestational diabetes risk, improves labor outcomes, and lowers complications for both mother and baby. Achieving weight loss goals through GLP-1 treatment before conception, then discontinuing safely, offers lasting metabolic advantages.
How does the Precision Peptide Genetic Test help with family planning?
The Precision Peptide Genetic Test ($99 add-on) identifies how your body's GLP-1 and other peptide pathways respond to medications, informing your long-term weight strategy. Understanding your genetic predispositions helps you and your provider plan more effectively around pregnancy timelines and post-pregnancy recovery goals.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can a 12 Year Old Take Ozempic for Weight Loss? A Comprehensive Look
Does Zepbound Have the Same Side Effects as Ozempic?